Background. Directly administered antiretroviral therapy (DAART) in methadone clinics has the potential to improve treatment outcomes for human immunodeficiency virus (HIV)-infected injection drug users (IDUs).
such as HIV-infected injection drug users (IDUs), may be beneficial.
HIV-infected drug users are often urban poor people or members of racial or ethnic minorities and have a high prevalence of psychiatric comorbidity [4] -all of which are factors that increase the risk of disenfranchisement. IDU continues to be a major HIV transmission factor worldwide. Substance abuse has been linked to nonadherence to treatment [5, 6] , and HIV disease progression has been reported to be higher among IDUs than among non-IDUs in the HAART era, whereas disease progression rates had been similar before the availability of effective therapy [7] [8] [9] . Inter-ventions that foster the integration of HIV medical treatment and substance abuse treatment are conceptually appealing for complex patient populations [10] [11] [12] .
Directly observed therapy for tuberculosis has been a successful approach for addressing concerns analogous to those commonly confronted in HIV management: maximizing adherence and clinical response to treatment and avoiding drug resistance [13] [14] [15] . However, the noncurative nature of HIV treatment and the dosing requirements for antiretroviral therapy have raised questions about the ability to translate the directly observed therapy model to HIV care [16, 17] . Methadone maintenance therapy may provide a framework for which long-term, directly administered antiretroviral therapy (DAART) is feasible [18, 19] . In this article, we report the results of a 4-year clinical trial of DAART in which treatment outcomes are compared with the outcomes of concurrent cohort comparison patients who took HAART on a self-administered basis.
METHODS
The DAART study. In April 2001, we initiated a prospective study of DAART at a university-affiliated methadone clinic in Baltimore, Maryland; preliminary results have been presented elsewhere [20] . In September 2003, the project was extended to 2 community-based methadone clinics in the city. Participants at the 3 methadone clinics were actively recruited, and an ongoing attempt was made to approach all potentially eligible individuals. At each site, the study staff encouraged substance abuse counselors to refer all patients who were known to be HIV infected for an assessment of study eligibility and to see whether they had interest in participating in the study. In addition, flyers that presented details about the study were distributed. Finally, referrals were sought from local clinicians who provided care for HIV-infected patients in the methadone programs. Participants were eligible for the study if they (1) were HIV infected; (2) were у18 years of age; (3) had a regular HIV treatment provider; (4) had received methadone therapy for 130 days, with no plans to discontinue; (5) were starting a first or subsequent HAART regimen in which doses were not administered more frequently than twice daily; (6) had a baseline HIV-1 RNA level 1500 copies/mL; and (7) did not have known triple-class antiretroviral drug resistance, as determined from a prior resistance test performed in clinical practice. Triple-class antiretroviral drug resistance was defined according to International AIDS Society-USA interpretive guidelines for genotypic resistance mutations [21] , as follows: (1) у3 nucleoside reverse-transcriptase mutations (excluding M184V), (2) у1 primary or у2 secondary nonnucleoside reverse-transcriptase inhibitor mutations, and (3) у3 protease inhibitor mutations, including at least 1 primary mutation. Antiretroviral regimens were selected by the participants' HIV treatment providers. Antiretroviral medications were prepackaged by an HIV specialty pharmacy in labeled, resealable plastic bags. Participants received supervised doses of HAART on each morning that they attended the methadone clinic. A nurse or medical assistant observed ingestion of the antiretrovirals in a private room that was distinct from the methadone-dispensing window. Evening doses and doses to be taken on methadone take-home days were prepackaged and given to participants for self-administration. Participants were also given a 3-day emergency supply of medications for use in case of unplanned absences from the methadone clinic. The treatment goal was to provide DAART for at least 1 year, but participants could continue DAART for longer if they wished. Participants who discontinued or were discharged from methadone maintenance therapy were no longer eligible to continue DAART, but they may have continued to receive HAART at the discretion of their HIV treatment provider. Clinical laboratory assessments, including determination of HIV-1 RNA levels and CD4 cell counts, were obtained as part of clinical care and not by study protocol. Study follow-up was censored at the 3 sites at the conclusion of the study (March 2005) . DAART participants provided written informed consent, and the DAART protocol was approved by the institutional review boards of Johns Hopkins University (Baltimore, MD) and the Centers for Disease Control and Prevention (Atlanta, GA). Johns Hopkins HIV Cohort and selection of comparison groups. The Johns Hopkins HIV Cohort has collected data on 15000 HIV-infected individuals who received longitudinal care in the clinic since 1990 [22] . Detailed demographic, behavioral, psychosocial, pharmaceutical, laboratory, and clinical data are abstracted by trained medical technicians at times corresponding to enrollment in the clinic and at 6-month intervals thereafter. The cohort study was approved by the Johns Hopkins Institutional Review Board, and participants provided written informed consent.
To gauge the relative efficacy of DAART, comparison patients who took HAART on a self-administered basis were selected from the cohort database. All patients in the cohort who initiated a first or subsequent regimen on or after 1 January 2001 were included in the analysis, to match the temporal availability of antiretroviral drugs to that of the DAART group. Comparison patients also had to have a baseline HIV-1 RNA level 1500 copies/mL and to not have documented triple-class drug resistance (using the same genotypic criteria as in DAART participants) to be included in the analysis. Comparison patients were divided into 3 groups. The IDU-methadone group included patients with a history of IDU who were receiving methadone therapy at the time that HAART was initiated. This group was meant to approximate, as closely as possible, the behavioral and psychosocial factors of the DAART participants. Second, (31) 48 ( NOTE. Data are no. (%) of patients, unless otherwise indicated. IDU-methadone, injection drug users who were receiving methadone treatment; IDUnonmethadone, injection drug users who were not receiving methadone treatment; IQR, interquartile range; non-IDU, patients who did not use injection drugs; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor. a , compared with the DAART group. P ! .05 b Resistance to individual classes was defined on the basis of the International AIDS Society-USA interpretive guidelines, as described in Methods. Nineteen DAART participants from one of the satellite community-based methadone clinics were excluded because results of prior resistance tests were not recorded.
the IDU-nonmethadone group included patients who had a history of IDU but who were not receiving methadone therapy. This group was included to assess whether methadone maintenance therapy itself was associated with treatment outcomes. Third, the non-IDU group comprised patients who had no history of IDU and who presumably did not have IDU-associated barriers to treatment adherence. The baseline time for DAART participants and comparison patients was the date that the HAART regimen in question was started. History of IDU was defined on the basis of whether IDU was identified as a risk factor for HIV infection at the time of enrollment to the cohort.
Statistical analysis. Statistical analysis was conducted using Stata software, version 8 (Stata). Baseline demographic and clinical factors were compared in the DAART group and in the 3 cohort comparison groups. Discrete variables were compared by the x 2 test, and continuous variables were compared by the Wilcoxon rank sum test. P values were 2-sided and were considered to be statistically significant if . We used the P ! .05 intention-to-treat (ITT) analytical principle, whereby patients (in the DAART group or in comparison groups) were included in 6-month and 12-month analyses if 1182 days and 1365 days, respectively, had elapsed as of 15 March 2005 (the censor date).
HIV-1 RNA levels !400 copies/mL in the 0-6-month and the 6-12-month time periods were compared between the DAART group and the cohort comparison groups using an ITT approach in which patients with missing values were considered to have experienced treatment failure. We also compared the proportions of patients with missing values in the groups, and in a secondary analysis, we compared the proportions of patients who achieved viral suppression by an ITT analysis, in which missing values were excluded. In a subset of participants with available data, we compared the time to discontinuation of HAART for у14 days using Kaplan-Meier estimates and a Cox proportional hazards model. Changes from the baseline value in log 10 HIV-1 RNA level and CD4 cell count were compared at 6 months and 12 months using an ITT approach in which the last observation was carried forward. Factors associated with achieving an HIV-1 RNA level !400 copies/mL in either the 0-6-month period or the 6-12-month period were assessed using a generalized estimating equation, to adjust SEs for repeated observations in the same subject [23] . In this Figure 1 . Percentage of subjects achieving an HIV RNA level !400 copies/mL in the directly administered antiretroviral therapy (DAART) group and in cohort comparison groups in the 0-6-month and 6-12-month time frames, as calculated using an intent-to-treat, missing-equals-failure rule. Point estimates and pair-wise significance test results are shown above the bars. IDU-meth, injection drug users who were receiving methadone treatment; IDU-nonmeth, injection drug users who were not receiving methadone treatment; non-IDU, patients who did not use injection drugs. Median log 10 HIV RNA levels in the directly administered antiretroviral therapy (DAART) group and in cohort comparison groups. At 6 months, the median decrease in the HIV-1 RNA level from baseline was 2.5 log 10 copies/mL in the DAART group, compared with 1.3 log 10 copies/ mL for injection drug users who were receiving methadone treatment (the IDU-meth group; ), 1.5 log 10 copies/mL for injection drug users P p .001 who were not receiving methadone treatment (the IDU-nonmeth group; ), and 2.0 log 10 copies/mL for patients who were not using injection P p .001 drugs (the non-IDU group;
). At 12 months, the median decrease in the HIV-1 RNA level from baseline was 2.4 log 10 copies/mL in the DAART P p .05 group, compared with 1.2 log 10 copies/mL in the IDU-meth group ( ), 0.9 log 10 copies/mL in the IDU-nonmeth group ( ), and 1.7 log 10 P p .08 P p .018 copies/mL in the non-IDU group ( ). P p 0.23 model, no assumptions were made about missing viral load data. Variables that differed between DAART participants and comparison patients or were associated with viral suppression ( ) were included in the model. Potential interactions were P ! .1 assessed by combining terms in regression models.
RESULTS
A total of 82 subjects participated in DAART (57 at the university-associated methadone clinic and 25 at the 2 community methadone clinics). A total of 809 cohort comparison patients were included in the analysis (75 patients in the IDU-methadone group, 244 in the IDU-nonmethadone group, and 490 in the non-IDU group). Baseline characteristics of the DAART and cohort comparison groups are shown in table 1. DAART participants were more likely to be female than were patients in the cohort comparison groups. The university-associated methadone clinic at which most DAART participants were enrolled had a dedicated program for uninsured, HIV-infected women that contributed to the relatively high percentage of women enrolled in DAART. DAART participants were significantly older than were patients in the non-IDU group. DAART participants were significantly more likely to be antiretroviral naive than were patients in the IDU-nonmethadone and the non-IDU groups. DAART participants initiated treatment significantly later than did subjects in the cohort comparison groups. Baseline HIV-1 RNA levels, CD4 cell counts, and results of prior resistance tests were similar in the DAART and cohort comparison groups. Compared with patients in the cohort comparison groups, DAART participants were less likely to use a nonnucleoside reverse-transcriptase inhibitor-based regimen but more likely to use a regimen in which doses were taken once daily.
The median duration of DAART participation was 10.3 months (interquartile range, 3.5-20.8 months). Of the 82 ), P p .12 30 cells/mm 3 for injection drug users who were not receiving methadone treatment (the IDU-nonmeth group; ), and 72 cells/mm 3 for patients P p .015 who were not using injection drugs (the non-IDU group;
). At 12 P p .93 months, the median increase in the CD4 cell count from baseline was 74 cells/mm 3 DAART participants, 39 (48%) discontinued DAART before the end of the study. Of these 39 patients, 22 (56%) discontinued DAART because they withdrew or were discharged from the methadone program, 15 (38%) discontinued it because they discontinued antiretroviral therapy, 1 (3%) discontinued it because the participant wished to stop DAART but to continue receiving both HAART and methadone, and 1 (3%) died while receiving DAART. The retention to HAART at 3 months was 83% in the DAART group, compared with 61% in the IDUmethadone group (hazards ratio [HR], 2.2; 95% CI, 1.2-3.8), 73% in the IDU-nonmethadone group (HR, 1.8; 95% CI, 1.1-3.0), and 80% in the non-IDU group (HR, 1.2; 95% CI, 0.7-2.0).
The percentages of DAART participants and patients in the cohort comparison groups who achieved viral suppression, according to the ITT missing-equals-failure principle, are shown in figure 1. In the 0-6-month and 6-12-month periods, the proportion of patients with missing HIV-1 RNA values in the DAART group (5% and 18%, respectively) was significantly lower than that in the IDU-methadone group (21% and 35%, respectively) and in the IDU-nonmethadone group (18% and 34%, respectively), but the proportion did not significantly differ from that in the non-IDU group (12% and 25%, respectively). Using an ITT analysis in which missing values were excluded, 78% and 68% of patients in the DAART group achieved viral suppression in the 0-6-month and 6-12-month periods, respectively, compared with 52% ( ) and 50% P p .002 ( ) in the IDU-methadone group, 61% ( ) and P p .08 P p .009 50% ( ) in the IDU-nonmethadone group, and 68% P p .03 ( ) and 58% ( ) in the non-IDU group. Longi-P p .08 P p .18 tudinal changes in viral load and CD4 cell counts are shown in figures 2 and 3, respectively.
Unadjusted and adjusted estimates of factors associated with viral suppression are shown in table 2. After adjustment for other factors, participants in the DAART group were significantly more likely to achieve viral suppression than were patients in each of the 3 cohort comparison groups. Other factors that were significantly associated with viral suppression in the multivariate model included white race/ethnicity, older age, antiretroviral-naive status before treatment initiation, lower HIV-1 RNA level at baseline, and measurement of the viral load in the 0-6-month period (compared with the 6-12-month period). Type of antiretroviral regimen, regimen dosing frequency (once or twice daily), prior results of antiretroviral-resistance tests, and calendar period were not significantly associated with viral suppression after adjustment for other factors. No statistically significant interactions were detected in the model.
DISCUSSION
We found that DAART, when given in conjunction with methadone therapy, was feasible and was associated with improved virologic outcomes, compared with the results for 3 groups of cohort comparison patients drawn from same urban catchment area as DAART participants. Two comparison groups included patients with a history of IDU, a characteristic shared with all DAART participants; these groups were distinguished only by whether they were receiving methadone treatment at the time that HAART was initiated or switched. Virologic and immunologic treatment outcomes for DAART participants were strikingly better than those observed in either of the IDU comparison groups. Additionally, the percentage of patients who achieved viral suppression in the DAART group at 6 months was significantly higher than that for the non-IDU comparison group, which was included to provide an additional metric by which to evaluate the treatment outcomes of the DAART group. The percentage of patients who achieved viral suppression at 12 months was also higher in the DAART group than in the non-IDU group, although the difference was of borderline significance, and increases in the CD4 cell count were similar in the 2 groups.
Prior analyses from our cohort have consistently found that IDUs have had worse virologic, immunologic, and clinical responses to HAART, compared with patients who were not IDUs [2, 5, 7] . Our finding that DAART was associated with improved outcomes for patients enrolled in a methadone clinic is encouraging. Similar to our intervention, researchers from British Columbia, Canada [18] , and from Ireland [19] have Table 2 . Unadjusted and adjusted estimates of factors associated with achieving an HIV-1 RNA level !400 copies/mL during follow-up. NOTE. IDU-methadone, injection drug users who were receiving methadone treatment; IDU-nonmethadone, injection drug users who were not receiving methadone treatment; IQR, interquartile range; non-IDU, patients who did not use injection drugs; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a OR per log 10 increase in HIV-1 RNA level.
reported promising results from studies in which DAART was provided in methadone-maintenance clinics. Compared with DAART participants, patients in the IDU comparison groups were significantly more likely to have missing HIV-1 RNA values during follow-up and were at significantly higher risk of discontinuing HAART for у14 days. These findings imply that one mechanism by which DAART may improve virologic responses in this disenfranchised population is to increase retention in treatment programs. However, DAART participants experienced higher rates of viral suppression than did participants in the IDU comparison groups, even when missing values were excluded. Increased antiretroviral adherence is an additional mechanism by which DAART may improve treatment outcomes, although this hypothesis could not be directly assessed in this study, because adherence was not measured in cohort patients. Buprenorphine is a partial opioid agonist that is effective in the management of opioid dependence, and unlike methadone, it may be prescribed by physicians and administered in primary care clinics [24] . The integration of DAART or other adherence interventions with buprenorphine therapy in HIV clinics may be an additional way in which to build on this paradigm. The preliminary body of research regarding supervised therapy models for HIV treatment has raised several questions and suggested directions for future study. DAART models have generally followed 1 of 2 approaches: community-based models with outreach workers [25] [26] [27] or models in which DAART is provided from within an existing programmatic framework, such as prisons [28, 29] , methadone clinics [18, 19] , residential treatment centers [30, 31] , and mobile health vans [32] . These 2 approaches have complimentary benefits and drawbacks. The community-based approach is flexible, in that patients with documented adherence difficulties and advanced HIV disease (for whom the benefits of effective HAART can be most quickly realized) can be specifically targeted. However, outreach workers are likely limited in how many patients they can reach each day, and such programs may be resource intense and difficult to sustain. Conversely, DAART models that are integrated into an existing framework are less flexible with regard to which patients they target, but such models may be more sustainable.
Most DAART interventions reported to date have either yielded noncomparative results [18, 19, 25, 26] or have used nonrandomized comparison groups [28, 29] . There is a clear need for randomized, controlled trials of promising DAART strategies going forward, and several such trials are underway [27, 32, 33] . Additionally, studies of the costs incurred by various DAART strategies and an assessment of their cost effectiveness will be important in assessing the public health priority of such approaches. Owing to the substantial benefits of effective HAART, an exploratory cost-effectiveness analysis by Goldie et al. [34] suggested that even relatively intensive and expensive adherence interventions may meet standard benchmarks for cost-effectiveness, particularly when directed to individuals with advanced HIV disease.
An important limitation of our study was that the comparison groups were not randomized. Selection bias or a nonspecific salutary effect from participating in a clinical trial cannot be excluded as potentially influencing the results we observed. We believe that several characteristics of our analysis mitigatebut do not eliminate-this concern. First, cohort patients were drawn from the same urban catchment area as DAART participants. Baseline demographic and clinical factors were generally similar in the DAART and cohort comparison groups. In addition, the vast majority of DAART participants received their HIV primary care through the Johns Hopkins HIV service, as did all of the cohort comparison patients. This means that the general treatment environment and approach to antiretroviral management were similar for the DAART participants and the cohort comparison groups. Second, we used 3 cohort comparison groups to provide a more robust perspective on treatment outcomes in DAART participants. Third, in a multivariate model, in which all known potential confounding variables were included, the likelihood of achieving viral suppression was significantly higher in the DAART group than in the cohort comparison groups.
In conclusion, we found that it was feasible to integrate DAART into a methadone clinic setting and that doing so was associated with improved virologic and immunologic outcomes, compared with findings for cohort comparison groups of IDUs taking HAART on a self-administered basis. Viral suppression rates were also higher in the DAART group than in a non-IDU cohort comparison group, although the differences were smaller and of borderline statistical significance. Acknowledging the limitations of nonrandomized comparison groups, these results suggest that methadone clinic-based DAART has the potential to provide substantial clinical benefit, and randomized, clinical trials of this approach are warranted.
